Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof

Abstract

Provided herein are solid forms comprising (a) 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (Lenalidomide) and (b) a coformer. Pharmaceutical compositions comprising the solid forms and methods for treating, preventing and managing various disorders are also disclosed.

What is claimed is: 
     
         1 . A solid form comprising (a) 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, prodrug, or clathrate thereof; and (b) a coformer. 
     
     
         2 . The solid form of  claim 1 , wherein the coformer is benzoic acid, gallic acid, glycolic acid, hippuric acid, magnesium bromide, malonic acid, maltol, oxalic acid, propyl gallate, sodium lauryl sulfate, L-tartaric acid, vanillic acid, or zinc chloride. 
     
     
         3 . The solid form of  claim 2 , wherein the coformer is benzoic acid. 
     
     
         4 . The solid form of  claim 2 , wherein the coformer is gallic acid. 
     
     
         5 . The solid form of  claim 2 , wherein the coformer is glycolic acid. 
     
     
         6 . The solid form of  claim 2 , wherein the coformer is hippuric acid. 
     
     
         7 . The solid form of  claim 2 , wherein the coformer is magnesium bromide. 
     
     
         8 . The solid form of  claim 2 , wherein the coformer is malonic acid. 
     
     
         9 . The solid form of  claim 2 , wherein the coformer is maltol. 
     
     
         10 . The solid form of  claim 2 , wherein the coformer is oxalic acid. 
     
     
         11 . The solid form of  claim 2 , wherein the coformer is propyl gallate. 
     
     
         12 . The solid form of  claim 2 , wherein the coformer is sodium lauryl sulfate. 
     
     
         13 . The solid form of  claim 2 , wherein the coformer is L-tartaric acid. 
     
     
         14 . The solid form of  claim 2 , wherein the coformer is vanillic acid. 
     
     
         15 . The solid form of  claim 2 , wherein the coformer is zinc chloride. 
     
     
         16 . The solid form of any one of  claims 1  to  15 , wherein the molar ratio of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione to the coformer is about 1:1. 
     
     
         17 . The solid form of any one of  claims 1  to  16 , which is substantially crystalline. 
     
     
         18 . The solid form of any one of  claims 1  to  17 , which is substantially a cocrystal. 
     
     
         19 . The solid form of any one of  claims 1  to  18 , which is greater than 80% by weight, greater than 90% by weight, greater than 95% by weight, greater than 97% by weight, or greater than 99% by weight a cocrystal. 
     
     
         20 . The solid form any one of  claims 1  to  19 , which is substantially physically pure. 
     
     
         21 . The solid form of  claim 20 , which is substantially free of other solid forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. 
     
     
         22 . The solid form of any one of  claims 1  to  21 , which is substantially chemically pure. 
     
     
         23 . The solid form of any one of  claims 1  to  22 , which is substantially free of solvent. 
     
     
         24 . The solid form of any one of  claims 1  to  23 , which is substantially free of water. 
     
     
         25 . The solid form of any one of  claims 1  to  24 , further comprising amorphous 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. 
     
     
         26 . The solid form of claim any one of  claims 1  to  25 , which is stable. 
     
     
         27 . The solid form of claim any one of  claims 1  to  26 , which is substantially crystalline and thermally stable. 
     
     
         28 . A pharmaceutical composition comprising the solid form of any one of  claims 1  to  27 . 
     
     
         29 . The pharmaceutical composition of  claim 28 , further comprising a pharmaceutically acceptable excipient or carrier. 
     
     
         30 . The pharmaceutical composition of  claim 28  or  29 , which is a single unit dosage form. 
     
     
         31 . The pharmaceutical composition of any one of  claims 28  to  30 , which is a tablet. 
     
     
         32 . The pharmaceutical composition of any one of  claims 28  to  31 , which is a capsule. 
     
     
         33 . The pharmaceutical composition of any one of  claims 28  to  32 , wherein the lenalidomide is in an amount of from about 0.1 to about 5 mg. 
     
     
         34 . A method of treating a disease, comprising administering the solid form of any one of  claims 1  to  27  or the pharmaceutical composition of any one of  claims 28  to  33  to a subject in need thereof. 
     
     
         35 . The method of  claim 34 , wherein the disease is multiple myeloma. 
     
     
         36 . The method of  claim 34 , wherein the disease is transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 
     
     
         37 . The method of any one of  claims 34  to  36 , further comprising administering a second active agent. 
     
     
         38 . The method of any one of  claim 37 , wherein the second active agent is dexamethasone. 
     
     
         39 . The method of any one of  claims 34  to  38 , wherein the subject was previously treated with a prior therapy.